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Blocking Cold-Inducible RNA-Binding Protein (CIRP) Protects 
Liver from Ischemia/Reperfusion Injury
Andrew Godwin*, Weng-Lang Yang*,†, Archna Sharma†, Adam Khader*, Zhimin Wang†, 
Fangming Zhang†, Jeffrey Nicastro*, Gene F. Coppa*, and Ping Wang*,†
*Department of Surgery, Hofstra North Shore-LIJ School of Medicine, Manhasset, New York
†Center for Translational Research, The Feinstein Institute for Medical Research, Manhasset, 
New York
Abstract
Cold inducible RNA-binding protein (CIRP) is a nuclear protein which has been recently 
identified as a novel inflammatory mediator in hemorrhagic shock and sepsis. We hypothesized 
that CIRP acts as a potent inflammatory mediator in hepatic ischemia-reperfusion (I/R), and thus 
blocking CIRP protects against I/R-induced liver injury. Male C57BL/6 mice were subjected to 
70% hepatic ischemia by microvascular clamping of the hilum of the left and median liver lobes 
for 60 min, followed by reperfusion. Anti-CIRP antibody (1 mg/kg body weight) or vehicle 
(normal saline) in 0.2 mL was injected via the internal jugular vein at the beginning of the 
reperfusion. Blood and liver tissues were collected 24 h after I/R for various measurements and a 
10-day survival study was performed. CIRP released into the circulation was significantly 
increased 24 h after hepatic I/R. Anti-CIRP antibody treatment markedly reduced hepatocellular 
damage markers and significantly improved the liver microarchitecture. Anti-CIRP also reduced 
the systemic and local inflammation demonstrated by attenuation in both serum and hepatic levels 
of interleukin 6. The expression of neutrophil-attracting chemokine as well as liver neutrophil 
infiltration was reduced by anti-CIRP treatment. Anti-CIRP also dramatically decreased the 
amount of apoptosis and nitrosative stress, evidenced by decrease in TUNEL staining and 
inducible nitric oxide synthase and cyclooxygenase-2 levels, respectively. Finally, the 10-day 
survival rate was increased from 37.5% in the vehicle group to 75% in the anti-CIRP treatment 
group. Thus, targeting CIRP offers potential therapeutic implications in the treatment of hepatic 
I/R injury.
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Introduction
Hepatic ischemia-reperfusion (I/R) injury can occur in a variety of clinical settings that 
include but not limited to trauma, liver resections, orthotopic transplantation, or prolonged 
shock states (1, 2). In the setting of liver transplantation, hepatic I/R contributes up to 10% 
of early organ failure as well as creating a higher incidence of both acute and chronic 
rejection (3). There is a multifarious interaction between hepatocytes, sinusoidal endothelial 
cells, and Kupffer cells as well as infiltrating neutrophils, macrophages, and platelets. The 
proinflammatory signaling mediators on all of these cell types become activated as a 
consequence of tissue anoxia and are further exacerbated upon reperfusion (1). Many 
attempts have been made to apply pharmacologic therapies or modify surgical approaches to 
reduce or help protect against hepatic I/R injury with limited success (4, 5). Therefore, 
identification of novel targets for developing therapeutic interventions to treat liver I/R 
injury is still under intensive research.
In the clinic, it would be challenging to protect against the ischemic damage in advance. 
After its occurrence, one can explore only a few avenues to help alleviate the hepatic I/R 
injury. One way is to reduce the milieu of inflammation, which is a major contributing factor 
to the injury. The inflammatory response associated with hepatic I/R is considered as a 
sterile type, which is not triggered by bacterial infection (6, 7). Such an inflammatory 
reaction is in response to the free radicals generated from acute oxidative and nitrosative 
stress during I/R (6). Another initiation of sterile inflammation is caused by the release of 
endogenous damage-associated molecular patterns (DAMPs) from host cells during injury 
(6-8). DAMPs can interact with pattern-recognition receptors, such as toll-like receptor 
(TLRs) and receptors of advanced glycation end products (RAGEs), in immune cells to 
activate the NF-κB signaling pathway for proinflammatory cytokine release (7, 9)
Cold-inducible RNA-binding protein (CIRP) is a 172-amino acid nucleoprotein that belongs 
to the family of cold shock proteins (10, 11). It has one N-terminal consensus-sequence 
RNA-binding domain and one C-terminal glycine-rich domain (10). CIRP is originally 
identified to facilitate the translation by stabilizing mRNAs when cells are under certain 
stressful circumstances, including hypothermia, exposure to ultraviolet irradiation, or 
hypoxia (9, 11). Human CIRP mRNA is constitutively expressed in various cell lines from 
different organ origins, including blood, liver, kidney, cervix, and urinary bladder (10). 
However, the expression of CIRP in human tissues has not been reported yet, except our 
recent study shown in serum (11). Recently, our laboratory identified that extracellular CIRP 
acts as a DAMP to accentuate the inflammatory response through binding to TLR4 and 
myeloid differentiation factor 2 (MD2) complex (11-13). Also, neutralizing antiserum to 
CIRP attenuates the inflammatory response in the settings of hemorrhagic and septic shock 
(11).
In our recent study, we have observed a significant increased CIRP expression in the liver of 
rats which underwent hemorrhagic and septic shock (11). In this study, we hypothesized that 
CIRP plays an important role in the pathogenesis of I/R-induced hepatic injury. To 
investigate this, we used an established mouse model of hepatic I/R injury and first measure 
the levels and kinetics of CIRP release in the serum after I/R. We then further examined the 
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effect of anti-CIRP antibody treatment on organ damage, inflammatory response, neutrophil 
infiltration, apoptosis, and oxidative stress. Finally, we evaluated the efficacy of anti-CIRP 
antibody treatment on the survival of mice after being subjected to hepatic I/R injury.
Materials and Methods
Experimental animals
Adult male C57BL/6 mice (20-25g) from Charles River Laboratories (Wilmington, Mass) 
were housed in a temperature controlled room on a 12-h light-dark cycle and fed a standard 
laboratory diet. Upon acquisition, mice were allowed to acclimate to the environment in our 
facility 5-7 days before the experiment. All mice were housed in cages of five members and 
animals were fasted overnight before undergoing surgery, but allowed water ad libitum. All 
experiments were performed in strict accordance with National Institute of Health guidelines 
for the use of experimental animals, and this study approved by the Institutional Animal 
Care and Use Committee of the Feinstein Institute for Medical Research.
Animal model of hepatic I/R
Mice were randomly assigned to three groups; sham, vehicle (normal saline), or anti-CIRP 
antibody treatment. Hepatic I/R was performed as described previously (2, 14). Briefly, 
animals underwent induction of anesthesia with 2.5% inhalational isoflurane, after which the 
ventral abdomen was shaved and cleansed with 10% povidone-iodine wash. A 3-4 cm 
midline incision was performed, and the hilum of the liver was exposed, allowing for 
identification of the hepatic artery and portal vein. A microvascular clip was placed across 
the hilum of the left lateral and median lobes to produce 70% ischemia for 60 min. At the 
beginning of the reperfusion, 0.2 mL normal saline, non-immunized control IgG (1 mg/kg 
body weight, [BW]), or anti-CIRP antibody (1 mg/kg BW) (11) was injected via internal 
jugular vein. We also administered anti-CIRP antibody at 10 mg/kg BW in our preliminary 
study and found its effects not significantly different from 1 mg/kg BW. The neutralizing 
polyclonal anti-CIRP antibody was generated as antisera against purified recombinant 
murine CIRP from rabbits and the IgG fraction was isolated from antisera by immobilized 
immunopure protein-A and -G chromatography as described previously by us (11). Anti-
CIRP antibody inhibits the TNF-α release in macrophages stimulated with CIRP in a dose-
dependent manner (11). After closure of the abdomen, 1 mL bolus of normal saline was 
given i.p. and the anesthesia was withdrawn. After operation, 1.0% lidocaine was applied 
topically to the surgical incision site and vein cannulation. Sham operated animals 
underwent midline laparotomy alone, without hepatic ischemia or administration of any 
treatments. Core body temperature was monitored throughout the entire operation and 
maintained between 35.5°C to 37.0°C by the use of an indwelling rectal thermometer and a 
heating pad placed below the animals. Blood and liver samples were collected 24 h after 
ischemia and stored at -80°C before analysis.
Survival study
Following the process of hepatic I/R as described in the animal model, the remaining 30% of 
the non-ischemic liver portion was resected at the onset of reperfusion. Then, normal saline 
or anti-CIRP antibody (1 mg/kg BW) was injected via internal jugular vein. Without 
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resection, most of the animals which underwent hepatic I/R will live with 30% functionally 
non-ischemic liver for 10 days. The animals were then monitored daily to record the survival 
time.
Western blotting analysis
Liver tissues (100 mg) were lysed and homogenized in 300 μL lysis buffer (10 mM Tris-HCl 
pH 7.5, 120 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl 
sulfate) containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, Ind) using 
a sonic dismembrator on ice. Samples were centrifuged at 14,000 revolutions/min for 15 min 
at 4°C, and the supernatant collected. Following measurement of sample protein 
concentration by BioRad DC protein assay kit (Bio-RAD, Hercules, Calif), 50 μg samples 
were separated on 4% to 12% Bis-Tris gels and transferred to nitrocellulose membranes. 
Membranes were incubated with primary antibody against CIRP or β-actin (SantaCruz 
Biotechnologies, Santa Cruz, Calif). All protein bands were detected by species-specific 
infrared fluorescence secondary antibodies (1:10,000) and analyzed by the LI-COR Odyssey 
Fc Imager (LI-COR, Lincoln, Neb) and band intensity measured using the NIH Image J 
densitometric software.
Measurement of injury markers and interleukin 6 (IL-6)
Whole-blood samples were centrifuged at 4,000 revolutions/min for 12 min to collect serum. 
The activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and 
lactate dehydrogenase (LDH) in the serum were determined by assay kits from Pointe 
Scientific (Lincoln Park, Mich). Serum and liver tissue IL-6 levels were determine by an 
enzyme-linked immunosorbent assay (ELISA) kit specific for mouse IL-6 (BD Biosciences, 
San Diego, Calif). These assays were carried out according to the manufacturer's 
instructions.
qPCR analysis
Total RNA was extracted from the liver by TRIzol reagent (Invitrogen, Carlsbad, Calif) and 
was reverse-transcribed into cDNA using murine leukemia virus reverse transcriptase 
(Applied Biosystems, Foster City, Calif). A PCR reaction was carried out in a 24 μL 
containing 0.08 μmol of each forward and reverse primer, 2 μL cDNA, 9.2 μL H2O, and 12 
μL SYBR Green PCR Master Mix (Applied Biosystems). Amplification was conducted in 
an Applied Biosystems 7300 model under the thermal profile of 50°C for 2 min and 95°C 
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The level of mouse 
β-actin mRNA was used for normalization and each specific mRNA was conducted in 
duplicate. Relative expression of mRNA was calculated by the 2-ΔΔCt method, and results 
were expressed as fold change in comparison to the sham group. The sequence of primers 
for this study is listed as follows: IL-6, 5′-CCGGAGAGGAGACTTCACAG-3′ (forward) 
and 5′-CAGAATTGCCATTGCACAAC-3′ (reverse); MIP-2, 5′-
CCCTGGTTCAGAAAATCATCCA-3′ (forward) and 5′-
GCTCCTCCTTTCCAGGTCAGT-3′ (reverse); iNOS, 5′-
GGCAAACCCAAGGTCTACGTT-3′ (forward) and 5′-
GAGCACGCTGAGTACCTCATTG-3′ (reverse); COX-2, 5′-
CTCAGCCAGGCAGCAAATC-3′ (forward) and 5′-ACATTCCCCACGGTTTTGAC-3′ 
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(reverse); β-actin, 5′-CGTGAAAAGATGACCCAGATCA-3′ (forward) and 5′-
TGGTACGACCAGAGGCATACAG-3′ (reverse).
Histological evaluation of liver injury and immunostaining for neutrophils
Liver tissues were taken from the median lobe following 24 h of reperfusion and stored in 
10% formalin before being fixed in paraffin. Samples were then sectioned to 4 μm cuts and 
stained with hematoxylin–eosin (H&E). Liver parenchymal injury was then assessed in a 
blinded fashion using a semi-quantitative light microscopy evaluation. The histologic injury 
score for each sample was expressed as the sum of the individual scores given for five 
different parameters; cytoplasmic color fading, cellular vacuolization, sinusoidal congestion, 
necrosis, and erythrocyte stasis (15-17). Scores for each variable ranged from 0 (0%), to 1 
(1%-10%), 2 (10%-30%), 3 (30%-60%), 4 (>60%), with a highest possible score of 20. Each 
sample score was then averaged over 10 microscopic fields. For neutrophil staining, 
paraffin-embedded liver tissues were dewaxed in xylene and rehydrated in a graded series of 
ethanol. The slides were heated in 0.92% citric acid buffer (Vector Laboratories, 
Burlingame, Calif) at 95°C for 30 min. After cooling, the slides were incubated with 2% 
H2O2/60% methanol and blocked in normal rabbit serum/Tris-buffered saline. The anti-Gr-1 
antibody (BioLegend, San Diego, Calif) was applied and incubated overnight. The detection 
was carried out as per the instructions provided by an immunohistochemistry kit with 
NovaRED substrate from Vector Laboratories.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay
Apoptosis in liver tissue was identified by TUNEL assay using an In Situ Cell Death 
Detection Kit (Roche). The assay was conducted according to the manufacturer's 
instructions. The nucleus was stained with 4′,6-diamidino-2-phenylindole (DAPI).
Statistical analysis
All data are expressed as a mean ± SE and compared by one-way analysis of variance 
(ANOVA) and the Student-Newman-Keuls (SNK) test. Survival rates were analyzed by the 
Kaplan-Meier estimator and compared using a log-rank test. Differences in values were 
considered significant if p < 0.05.
Results
Circulating levels of CIRP are increased after hepatic I/R
To explore the role of CIRP as a potential inflammatory mediator in hepatic I/R, we 
examined the release of CIRP in serum by Western blotting at 1, 4, and 24 h after the start of 
the 60-min hepatic ischemia followed by reperfusion in mice. Serum CIRP was detectable in 
sham, still comparable to sham at 1 h, increased by 2.6-fold at 4 h and significantly elevated 
by 5.9-fold at 24 h after hepatic I/R (Fig. 1). These findings are consistent with our prior 
studies of increased CIRP release in hemorrhagic shock and sepsis (11), suggesting that 
CIRP plays an important role in triggering inflammatory responses in hepatic I/R as well.
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Anti-CIRP antibody treatment attenuates liver injury after hepatic I/R
Serum levels of hepatic damage markers AST, ALT, and LDH were increased by 21-, 34- 
and 62-fold, respectively, 24 h after hepatic I/R (Fig. 2A-C). With the administration of 
neutralizing antibody against CIRP at the beginning of reperfusion, significant reduction 
was seen in organ injury markers by 74%, 83%, and 68%, respectively (Fig. 2A-C). 
However, the AST, ALT, and LDH levels in mice treated with non-immunized control IgG 
(1 mg/kg BW) were comparable to the vehicle group (AST, 1501 ± 567 vs. 1509 ± 205 
IU/L; ALT, 543 ± 200 vs. 573 ± 236 IU/L; and LDH, 3502 ± 1256 vs. 2762 ± 656 IU/L - 
control IgG vs. vehicle). Further, these serum injury markers data correlated with the hepatic 
tissue architecture damaged observed by histological evaluation. Histological alterations 
seen in liver tissue samples 24 h after hepatic I/R were most evident for the degree of 
necrosis, micro-hemorrhage, and leukocyte infiltration in vehicle-treated animals in 
comparison to sham as well as anti-CIRP antibody-treated animals (Fig. 3A-C). 
Quantification of liver histologic injury score after hepatic I/R showed that vehicle-treated 
groups exhibited a 3.7-fold increase in severity compared to sham-operated animals, which 
was significantly reduced by 48% in anti-CIRP antibody-treated animals (Fig. 3D). Taken 
together, these results demonstrate that anti-CIRP antibody administration provides 
significant protection against liver injury from hepatic I/R.
Anti-CIRP antibody treatment inhibits the inflammatory response after hepatic I/R
To ascertain the systemic and local inflammatory responses to hepatic I/R in our model, IL-6 
levels were measured in both serum and liver tissue 24 h after hepatic I/R. Vehicle-treated 
animals showed an increase in serum IL-6 levels by 63-fold compared to sham group. When 
animals were administered anti-CIRP antibody, this increase in IL-6 levels was significantly 
reduced by 75% (Fig. 4A). In the liver tissue IL-6 protein levels increased by 2-fold in the 
vehicle-treated group compared to sham group, and anti-CIRP antibody treatment decreased 
it by 44% (Fig. 4B). Also, IL-6 mRNA increased by 18-fold in vehicle in comparison to 
sham, which was decreased by 94% in anti-CIRP treated group (Fig. 4C). Thus, anti-CIRP 
antibody administration resulted in downregulation of both systemic as well as local levels 
of proinflammatory marker IL-6.
Anti-CIRP antibody treatment reduces neutrophil infiltration into the liver after hepatic I/R
Hepatic I/R also results in overproduction of local proinflammatory chemokines, so we 
checked the expression of macrophage inflammatory protein 2 (MIP-2) in the liver tissue. 
The MIP-2 mRNA levels determined by qPCR dramatically increased by 179-fold in 
vehicle-treated mice compared to sham mice. However, MIP-2 levels were reduced by 80% 
in anti-CIRP antibody-treated group compared to vehicle group (Fig. 5A). Chemokines such 
as MIP-2 mediate tissue infiltration of neutrophils which release deleterious inflammatory 
mediators causing liver injury. To determine the degree of neutrophil infiltration associated 
with hepatic I/R, we performed immunohistochemistry staining of liver tissue for 
granulocyte receptor 1 (Gr-1), which is a marker for neutrophils. There is an abundance of 
neutrophils seen in vehicle group compared to sham, with a drastic reduction in anti-CIRP 
antibody-treated animals (Fig. 5B-D). Together, this data suggests that anti-CIRP antibody 
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administration not only reduces proinflammatory chemokines, but also decreases associated 
neutrophil recruitment to the liver.
Anti-CIRP antibody treatment decreases apoptosis after hepatic I/R
To examine whether anti-CIRP antibody treatment has any effect on apoptosis after hepatic 
I/R, we performed TUNEL assay which detects DNA fragmentation resulting from 
apoptosis, in the liver tissues 24 h after hepatic I/R. There were no TUNEL-positive cells 
(green spots) in the sham livers (Fig. 6A), but vehicle treated animals showed very 
prominent TUNEL-positive areas (Fig. 6B). After anti-CIRP antibody treatment there is a 
significant decline in TUNEL-positive areas in comparison to vehicle treated animals (Fig 
6C). Taking into account the H&E staining which showed necrosis, not apoptosis, in the 
majority of the hepatocellular damage, primary role of anti-CIRP antibody in hepatic I/R 
may not be protection from apoptosis, but reduction in apoptosis could be a secondary 
benefit.
Anti-CIRP antibody treatment reduces nitrosative stress after hepatic I/R
To determine the effect of anti-CIRP antibody treatment on the oxidative stress associated 
with hepatic I/R, we evaluated the liver tissue levels of iNOS and COX-2 at 24 h after 
hepatic I/R. We observed a 7.9-fold increase in iNOS mRNA expression in liver tissue of 
vehicle-treated I/R animals when compared to sham group, which was significantly reduced 
by 86% in anti-CIRP antibody-treated animals (Fig. 7A). COX-2 mRNA levels were also 
increased by 173-fold in vehicle treated group in comparison to sham, with a drastic 
reduction by 99% in anti-CIRP antibody-treated animals (Fig. 7B).
Anti-CIRP antibody treatment improves survival following a lethal model of hepatic I/R
To evaluate the potential survival benefit of neutralizing CIRP with anti-CIRP antibody, we 
used a total hepatic I/R model as previously described (2). We observed that only 37.5% of 
vehicle treated animals survived for 10 days after being subjected to hepatic I/R with 
subsequent partial hepatectomy of the non-ischemic portions of the liver. Whereas, the 10-
day survival rate under these conditions increased significantly to 75% in the anti-CIRP 
antibody treated group (Fig. 8). Thus, anti-CIRP antibody treatment doubled the survival 
rate of mice after hepatic I/R compared to vehicle controls.
Discussion
CIRP is a member of the family of cold shock proteins that respond to cold stresses by 
functioning as RNA chaperone to promote translation giving a survival advantage (10). 
However, our previous study has established that CIRP can be released and acts as a DAMP 
to induce inflammatory responses (9, 11). We have also shown that neutralizing antisera to 
CIRP attenuates inflammatory responses and improves the survival of hemorrhagic and 
septic animals (11). The purpose of the current study is to test the hypothesis that CIRP can 
also act as a mediator of inflammation and injury in hepatic I/R. Indeed, we find that CIRP 
levels increase in the serum in a time dependent manner after hepatic I/R. In particular, we 
show that blockade of CIRP protects against hepatic I/R injury with a decrease in systemic 
and local hepatic proinflammatory cytokine expression. We also demonstrate that blockade 
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of CIRP not only prevents the I/R associated neutrophil infiltration into the liver but also 
results in reduced hepatocyte apoptosis and oxidative stress. Finally, we reveal that 
administration of neutralizing antisera to CIRP significantly reduces the mortality rate to 
half in a lethal model of hepatic I/R.
Hepatic I/R injury has been shown to affect the function of multiple organ systems and 
cause systemic consequences (18, 19). Because hepatic I/R injury is seen in a variety of 
clinical settings and liver dysfunction creates such serious complications leading to possibly 
death, it makes this a topic for extensive research. The current understanding of the 
pathophysiology of hepatic I/R consists of complex interactions of multiple inflammatory 
pathways with the main contributors being from the production of reactive oxygen species, 
release of proinflammatory cytokines and chemokines, as well as the activation of immune 
cells that promote inflammation and tissue damage (20). The immune response generated 
during hepatic I/R lacks a microbial component, but instead is initiated by endogenous self 
proteins or DAMPs (6, 8). Although we did not examine the damage of other organs in this 
study, we expect there will be a systemic effect on other organs due to the elevation of CIRP 
in serum after hepatic I/R to induce inflammatory responses.
The extracellular delivery of DAMPs depends on their production by injured cells and the 
extent of the tissue injury (21). Activation of the immune system, specifically the innate 
immune cells by DAMPs has been under investigation for the past two decades. TLRs are 
pattern recognition receptors located both intra- and extra-cellularly, but differ from each 
other in ligand specificity, expression patterns, and in some instances signaling pathways 
(22-24). Recently, TLR4 has been revealed to play a pivotal role in multiple I/R models and 
its antagonism can attenuate the inflammatory response in I/R involving the heart, liver, and 
kidney (22, 25). Some DAMPs bind to the TLR4-MD2 complex on the surface of 
monocytes, macrophages, and neutrophils to generate a cytokine storm leading to damaging 
effect that is preceded by an ischemic insult (26).
CIRP has been found to be constitutively expressed in low amounts in various tissues and its 
expression is up regulated during cellular stress (11, 12, 27). The human CIRP gene has 
been mapped to chromosome locus 19p13.3 and is 95.3% identical to the amino-acid 
sequence to that of mouse CIRP (10). The redistribution of CIRP is not only attributed to 
necrosis, but it is also actively secreted from macrophages. The release of CIRP is not 
through the classical endoplasmic reticulum – Golgi apparatus, but through a lysosomal 
secretions process (11). This extracellular CIRP causes an induction of TNF-α, IL-6, and 
high-mobility group box 1(HMGB1) expression via engaging the TLR4-MD2 complex and 
activation of the NF-κB pathway (11, 27). Whether CIRP can suppress the production of 
anti-inflammatory cytokines needs further investigation. We believe that our study is first to 
report that CIRP plays a role in the generation of sterile inflammatory response in hepatic 
I/R. We found that serum CIRP levels increase in a time-dependent manner after hepatic 
I/R. Such increase is associated with the elevation of proinflammatory mediators IL-6 and 
MIP-2, and hepatocellular damage. These proinflammatory mediators drive neutrophils 
infiltrating the liver, which can exacerbate oxidative liver damages at the later stage of 
reperfusion (6). With administration of anti-CIRP antibody, the levels of local and systemic 
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IL-6 as well as liver MIP-2 expression are decreased, which is associated with the reduction 
of neutrophil infiltration and hepatocellular damage.
In addition, anti-CIRP antibody administration also decreases the cellular oxidative stress 
which plays an important role in the cellular damage during I/R injury (28). Upregulation of 
iNOS in I/R injury causes excessive production of nitric oxide which reacts with superoxide 
anion (O2-), creating peroxynitrite (ONOO-). Peroxynitrite then contributes to injury through 
lipid peroxidation, apoptosis, necrosis, and neutrophil recruitment by nitration of tyrosine 
residues on tissue proteins (29). Indeed, we observe that anti-CIRP antibody administration 
decreases the expression of iNOS and COX-2 as well as apoptosis in the liver after I/R. We 
believe this to be significant as previous studies have demonstrated that apoptosis is a key 
contributor to injury following hepatic I/R and that therapies aimed at reducing apoptosis 
have proven to be hepatoprotective (30). However, the initial I/R injury caused by reactive 
oxygen species, leading to activation of an inflammatory cascade and resulting in an 
increase of both apoptosis and necrosis (29, 31). There is a varying degree in the literature 
debating whether the primary mode of cell death in hepatic I/R is apoptosis or necrosis, and 
since apoptosis is an energy depended process necrosis should be the dominate pathway (28, 
29, 31, 32). In our study, we show by H&E large areas of necrosis and by TUNEL assay 
large areas of apoptosis in the vehicle group, which are both drastically reduced in the anti-
CIRP antibody-treated group. Therefore, regardless of which pathway is more prominent we 
show that blocking CIRP is beneficial in both ways.
Another DAMP protein HMGB1 has also been shown to be an early mediator of sterile 
inflammation (33, 34). Inhibition of HMGB1 activity with neutralizing antibody was also 
shown to significantly decrease liver damage after I/R, whereas administration of 
recombinant HMGB1 was shown to worsen I/R injury (35). We have previously shown that 
CIRP also drives HMGB1 release in macrophages and both bind to TLR4-MD2 complex 
and work additively in stimulating inflammatory response (11). It will be interesting to see if 
blocking both CIRP and HMGB1 together can provide an additive or synergistic protective 
benefit after hepatic I/R injury.
By attenuating the severe liver damage, anti-CIRP antibody provides a significant survival 
advantage to treat animals underwent hepatic I/R. To our knowledge, this represents the first 
study in which blocking of CIRP has improved a survival in animals when administered 
during the reperfusion phase of hepatic I/R. Antibody belongs to the biologics category in 
drug development and has less concern for toxicity when compared to chemical compounds. 
Whether the delayed administration of anti-CIRP antibody such as hours or even days after 
hepatic I/R still has a beneficial effect for clinical application in treatment needs to be 
investigated further. Although administration of anti-CIRP antibody improves the survival 
rate to 75%, it still does not provide a complete protection for animals from hepatic I/R 
injury. This suggests that factors other than CIRP may contribute to the lethality. Especially, 
when the liver undergoes such severe I/R damage, many intracellular components can be 
released and serve as DAMPs. It will be a challenge to identify each DAMP's contribution 
and its significance in deteriorating the organ; however, this study clearly demonstrates that 
CIRP is one of the major mediators to cause the mortality of animals after heptic I/R injury.
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In summary, CIRP is released into the circulation after hepatic I/R and acts as an 
endogenous proinflammatory mediator. CIRP can be effectively blocked with anti-CIRP 
antibody, which results in attenuating liver injury induced by I/R. It does so by decreasing 
the inflammatory response, infiltration of neutrophils, and iNOS-mediated oxidative 
damage. In addition, it provides a distinct survival advantage in a lethal model of hepatic 
I/R. In the light of these observations, it indicates that extracellular CIRP contributes 
significantly to the deterioration of liver after I/R injury and targeting CIRP may provide 
another strategy to manage such clinical condition.
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Fig. 1. Increased release of CIRP after hepatic I/R
Western blot analysis of CIRP in the serum samples collected from sham and hepatic I/R 
groups at the indicated times after the start of hepatic I/R procedure. Representative blots 
against CIRP and Ponceau S red staining (PS red) are shown. Blots were scanned and 
quantified with densitometry. Band intensity of CIRP was normalized to the corresponding 
band intensity of PS red staining. The value in sham group is designated as 1 for 
comparison. Data presented as means ± SE (n=3-4/group) and compared by one-way 
ANOVA and SNK method; *p < 0.05 vs. sham.
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Fig. 2. Effect of anti-CIRP antibody treatment on systemic organ injury markers after hepatic 
I/R
Serum samples were collected at 24 h post-hepatic I/R from sham, vehicle and anti-CIRP 
antibody-treated (Anti-CIRP) groups for measuring AST (A), ALT (B), and LDH (C). Data 
presented as means ± SE (n=6/group) and compared by one-way ANOVA and SNK 
method; *p < 0.05 vs. sham; #p < 0.05 vs. vehicle.
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Fig. 3. Effect of anti-CIRP antibody treatment on tissue damage and cellular architecture in the 
liver after hepatic I/R
Histologic evaluation of the liver in the sham (A), vehicle (B), and anti-CIRP antibody-
treated (C, Anti-CIRP) groups. Liver tissues were harvested 24 h after hepatic I/R, 
processed, and then stained with hematoxylin-eosin (H&E). Representative 
photomicrographs at 100× magnification. D, Semiquantitative histologic injury score 
measuring differences in cytoplasmic vacuolization, cytoplasmic fading, nuclear 
condensation, nuclear fading, nuclear fragmentation, and erythrocyte stasis examined on 
H&E staining as described in Materials and Methods. Data presented as means ± SE (n=4-5/
group) and compared by one-way ANOVA and SNK method; *p < 0.05 vs. sham; #p < 0.05 
vs. vehicle.
Godwin et al. Page 15
Shock. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4. Effect of anti-CIRP antibody treatment on systemic and local proinflammatory cytokine 
IL-6 levels after hepatic I/R
Serum samples and ischemic liver tissues were collected at 24 h post-hepatic I/R from sham, 
vehicle and anti-CIRP antibody-treated (Anti-CIRP) groups. IL-6 protein levels in serum 
(A) and liver tissue (B) were determined by enzyme-linked immunosorbent assay. (C) Liver 
IL-6 mRNA expression was determined by qPCR analysis and its levels were normalized to 
β-actin. The value in sham group is designated as 1 for comparison. Data presented as means 
± SE (n=6-7/group) and compared by one-way ANOVA and SNK method; *p < 0.05 vs. 
sham; #p < 0.05 vs. vehicle.
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Fig. 5. Effect of anti-CIRP antibody treatment on neutrophil infiltration into the liver after 
hepatic I/R
Ischemic liver tissues were collected at 24 h post-hepatic I/R from sham, vehicle and anti-
CIRP antibody-treated (Anti-CIRP) groups. (A) MIP-2 mRNA expression was determined 
by qPCR analysis and its levels were normalized to β-actin. The value in sham group is 
designated as 1 for comparison. Data presented as means ± SE (n=6/group) and compared 
by one-way ANOVA and SNK method; *p < 0.05 vs. sham; #p < 0.05 vs. vehicle. Liver 
tissues were immunostained against Gr-1, a marker for neutrophil infiltration. 
Representative photomicrographs from sham (B), vehicle (C), and anti-CIRP antibody-
treated (D, Anti-CIRP) groups at 100× magnification.
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Fig. 6. Effect of anti-CIRP antibody treatment on induction of apoptosis after hepatic I/R
Liver tissues were harvested at 24 h after hepatic I/R and sections subjected to TUNEL 
assay to detect DNA fragmentation. Representative TUNEL staining (green fluorescent) and 
nuclear counterstaining (blue fluorescent) of liver sections from sham (A), vehicle (B), and 
anti-CIRP antibody-treated (C, Anti-CIRP) groups at 100× magnification.
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Fig. 7. Effect of anti-CIRP antibody treatment on iNOS and COX-2 expression after hepatic I/R
The ischemic portions of the livers were harvested at 24 h post-hepatic I/R for measuring 
iNOS (A) and COX-2 (B) mRNA levels by qPCR analysis. iNOS and COX-2 mRNA 
expression levels were normalized to β-actin. The value in sham group is designated as 1 for 
comparison. Data presented as means ± SE (n=6/group) and compared by one-way ANOVA 
and SNK method; *p < 0.05 vs. sham; #p < 0.05 vs. vehicle.
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Fig. 8. Effect of anti-CIRP antibody treatment on survival in a lethal model of hepatic I/R
Survival rates over a 10-day period following 70% hepatic I/R with resection of the 
remaining non-ischemic 30% liver tissue are demonstrated for vehicle (black) and anti-CIRP 
antibody treatment (gray). Survival rates were analyzed by the Kaplan-Meier estimator 
using a log-rank test. *p < 0.05 vs. vehicle.
Godwin et al. Page 20
Shock. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
